Efficacy and Adverse Reactions of Carboplatin, Nab-Paclitaxel Regimen Combined with Atezolizumab in the Treatment of Non-Small Cell Lung Cancer

نویسندگان

چکیده

We attempt to study the efficacy and adverse reactions of carboplatin, nab-paclitaxel regimen combined with atezolizumab in non-small cell lung cancer treatment. randomly selected 120 patients who received therapy our hospital from January 2019 December 2021 divided them into two groups, 60 cases respectively. Treated control group carboplatin paclitaxel pembrolizumab, while observation albumin pembrolizumab. Compared both groups on efficacy, incidence reactions, levels peripheral blood lymphocyte subsets serum tumor markers. After treatment, possessed higher objective remission rate disease than (p<0.05); had lower during treatment period cluster differentiation 3+, 4+ 4+/cluster 8+ values group, but it (p<0.05). Observation cytokeratin 19 fragment antigen 21-l, squamous carcinoma antigen, carbohydrate 125 carcinoembryonic Carboplatin, treating can effectively alleviate their disease, reduce risk process improve body’s immune function, which is worthy promotion.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease.

There are few established treatments for patients with non-small-cell lung cancer (NSCLC) with interstitial lung disease (ILD). The safety and efficacy of albumin-bound paclitaxel (nab-paclitaxel) in combination with carboplatin is uncertain, although the combination of carboplatin and paclitaxel is the most common regimen for treating NSCLC patients with ILD. A total of 9 NSCLC patients with I...

متن کامل

Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease.

BACKGROUND Since advanced non-small cell lung cancer (NSCLC) patients with the interstitial lung disease (ILD) have been excluded from clinical trials, it is uncertain whether chemotherapy really provides a benefit to these patients. PATIENTS AND METHODS Fifteen advanced NSCLC patients with ILD that was detected on the chest X-rays were enrolled in this study. Carboplatin plus paclitaxel was ...

متن کامل

Paclitaxel/Carboplatin in the Treatment of Non-Small-Cell Lung Cancer

While it has long been accepted that chemotherapeutic intervention provided some benefit for patients with non-small-cell lung cancer (NSCLC) in terms of quality of life and symptomatology as well as modest improvements in survival,[1-3] the overall outlook for patients with this disease remained bleak. Despite development and evaluation of a number of agents found to produce at least a 15% res...

متن کامل

Paclitaxel/Carboplatin in the Treatment of Non-Small-Cell Lung Cancer

While it has long been accepted that chemotherapeutic intervention provided some benefit for patients with non-small-cell lung cancer (NSCLC) in terms of quality of life and symptomatology as well as modest improvements in survival,[1-3] the overall outlook for patients with this disease remained bleak. Despite development and evaluation of a number of agents found to produce at least a 15% res...

متن کامل

Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer.

Chemotherapeutic intervention in advanced and metastatic non-small-cell lung cancer (NSCLC) has changed over the past 2 decades. The improvements offered by cisplatin (Platinol)-based regimens, though significant in terms of survival and quality of life, were modest at best. Carboplatin (Paraplatin), which possesses a toxicity profile favorable to that of its parent analogue cisplatin, yielded ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Indian Journal of Pharmaceutical Sciences

سال: 2022

ISSN: ['0250-474X', '1998-3743']

DOI: https://doi.org/10.36468/pharmaceutical-sciences.spl.525